Market Report Source

Overview

Report Overview

Drugs in reproductive medicine are evolving into highly sophisticated products with multifunctional pharmacological properties and clinical utilities. Novel contraceptive formulations with low side-effect profiles are providing women with flexible birth-control and menstrual management options whilst also offering secondary indications to treat coexisting endocrinological and gynaecological disorders. Furthermore, the increasing global prevalence of infertility is driving R&D to offer novel drug solutions to improve or restore male- and female-factor infertility, optimize fertilization and embryo implantation, and reduce miscarriage. Recent advances in administering and formulating hormone-based drugs is enabling a revolution in contraception and infertility treatments. Over the next decade, the market for hormonal contraceptives and infertility drugs is predicted to expand considerably through innovation, new and expanding markets, and high-value prospects that importantly offer novel solutions to unmet needs and demands of patients who wish to modulate or enhance fertility. The current mature market for hormonal contraceptives and infertility drugs is estimated at US$7.1 billion but is forecast to increase 40% to US$9.9 billion by 2012. This report provides a detailed analysis of the global market for hormonal contraceptives and infertility drugs highlighting strategies for product extension and reformulation, sales forecasts to 2012 for leading products, and impact of late-stage pipeline drugs on the market. Therapy area forecasting and illustrative market data and analysis is also presented to offer insights into sector performance, which may enable the reader to make key assumptions about future markets and prospects. .

This report comments on strategic and commercial issues that may affect current product positioning and discusses key compounds that have the potential to become high-value products over the next decade. The report also provides insights into forthcoming market dynamics and product sales to 2012 to enable the reader to make assumptions about future markets and prospects, and utilize the data for proprietary predictive market modelling.

Table of Contents

List of Tables
List of Figures
Executive Summary
Objectives of the Report
Research Methodology

Chapter 1 Introduction to Reproductive Medicine
Ageing, Lifestyle Issues, and Reproductive Health
Elective Infertility – Contraception
The Birth of Contraception
Inducing Infertility via Ovulation Suppression
Combined Oral Contraceptives
Fertility Disorders
Assisted Conception

Chapter 2 Hormonal Contraceptives and Infertility Drug Markets
Reproductive Medicine Market Overview
Market Analysis: Contraception and Infertility

Hormonal Contraception
Contraceptive Formulations
Combined Oestrogen-Progestogen Contraceptives
Progestogen-Only Contraceptives
Product Market for Hormonal Contraceptives
Janssen-Cilag/Ortho-McNeil/Johnson & Johnson
Key Product and Portfolio Review
Sales Estimates and Product Market Outlook
Organon/Akzo Nobel
Key Product and Portfolio Review
Pipeline Focus
EMM 310066
Male Contraception – Organon/Schering
Sales Estimates and Product Market Outlook
Pharmacia/Pfizer
Key Product and Portfolio Review
Sales Estimates and Product Market Outlook
Schering/Berlex
Key Product and Portfolio Review
Pipeline Focus
Yaz
Contraceptive Patch
E2/DNG Pill
Male Contraception
Sales Estimates and Product Market Outlook
Wyeth
Key Product and Portfolio Review
Sales Estimates and Product Market Outlook
Barr Laboratories
Key Product and Portfolio Review
Pipeline Focus
Sales Estimates and Product Market Outlook
Promising Contraceptives in Research and Development
Male Contraception
University of Washington/National Institute of Child Health and Human
Development, USA
Miglustat
Nestorone Gel
Future Considerations and Outlook for the Contraceptive Product Market

Infertility Pharmacotherapeutics
Pharmacotherapies for Infertility
Mechanism of Action of Infertility Pharmacotherapeutics
Product Market Analysis for Infertility Pharmacotherapeutics
AstraZeneca
Key Product and Portfolio Review
Sales Estimates and Product Market Outlook
Ferring
Key Product and Portfolio Review
Pipeline Focus
Sales Estimates and Product Market Outlook
Organon
Key Product and Portfolio Review
Pipeline Focus
Sales Estimates and Product Market Outlook
Serono
Key Product and Portfolio Review
Pipeline Focus
Sales Estimates and Product Market Outlook
Future Considerations and Market Insights for Infertility Pharmacotherapeutics
Promising Infertility Drugs in Research and Development
Novel Female Infertility Pharmacotherapeutics
Vitropin – Vitro Diagnostics
PV903 – GroPep
Novel Male Infertility Pharmacotherapeutics
BIO316 – Enhance Biotech/Bioaccelerate
Menevit – Repromed, University of Adelaide
Commercial Prospects for Infertility Drugs

Chapter 3 Drugs in Research and Development
Contraception
Research and Development Overview
Infertility
Research and Development Overview

Chapter 4 Market Analysis, Therapy Forecasting, and Prospect Mining
Reproductive Medicine: Contraception and Infertility
Therapy Area Forecasts
Market Share of Reproductive Medicine Therapy Areas
Comparative Analysis: Product Sales
Prospect Mining
Contraception
Infertility
Therapy Area Forecasts: 2012 and 2020

Chapter 5 Report Synopsis
Contraception – Key Data Points
Infertility – Key Data Points
Reference Sources

List of Tables
Table 1.1 Global Prevalence Rates of Oral Contraceptive Use
Table 1.2 Popular Combined Oral Contraceptives, 2005
Table 1.3 Biological Causes of Infertility
Table 1.4 Assisted Conception Techniques
Table 2.1 Estimated Global Sales (US$) & Forecasts of Leading Hormonal Contraceptives and Infertility Drugs, 2004-2012
Table 2.2 Selection of Contraceptives Segmented by Formulation and Delivery Route
Table 2.3 Johnson & Johnson’s Hormonal Contraceptive Product Portfolio, 2005
Table 2.4 Estimated Sales (US$) and Annual Growth (%) of Ortho-McNeil / Johnson & Johnson’s Hormonal Contraceptive Portfolio, 2005-2012
Table 2.5 Organon/Akzo Nobel’s Hormonal Contraceptive Product Portfolio, 2005
Table 2.6 Estimated Sales (US$) and Annual Growth (%) of Organon/Akzo Nobel’s Hormonal Contraceptive Portfolio, 2005-2012
Table 2.7 Pfizer’s Hormonal Contraceptive Product Portfolio, 2005
Table 2.8 Estimated Sales (US$) and Annual Growth (%) of Pfizer’s Hormonal Contraceptive Portfolio, 2005-2012
Table 2.9 Schering/Berlex’ Hormonal Contraceptive Product Portfolio, 2005
Table 2.10 Schering/Berlex’ Pipeline Contraceptive Candidates, 2005
Table 2.11 Estimated Sales (US$) and Annual Growth (%) of Schering/Berlex’ Hormonal Contraceptive Portfolio, 2005-2012
Table 2.12 Wyeth’s Hormonal Contraceptive Product Portfolio, 2005
Table 2.13 Estimated Sales (US$) and Annual Growth (%) of Wyeth’s Hormonal Contraceptive Portfolio, 2005-2012
Table 2.14 Barr’s Hormonal Contraceptive Product Portfolio, 2005
Table 2.15 Estimated Sales (US$) and Annual Growth (%) of Barr’s Hormonal Contraceptive Portfolio, 2005-2012
Table 2.16 Pipeline Hormonal Contraceptives, 2005
Table 2.17 Pharmacotherapies for Infertility, 2005
Table 2.18 AstraZeneca’s Hormonal Infertility Product Portfolio, 2005
Table 2.19 Estimated Global Sales (US$) and Annual Growth (%) of AstraZeneca’s 68 Hormonal Infertility Products, 2005-2012
Table 2.20 Ferring’s Infertility Product Portfolio, 2005
Table 2.21 Estimated Global Sales (US$) and Annual Growth (%) of Ferring’s Infertility Drugs, 2005-2012
Table 2.22 Organon’s Hormonal Infertility Product Portfolio, 2005 72
Table 2.23 Estimated Global Sales (US$) and Annual Growth (%) of Organon’s Hormonal Infertility Products, 2005-2012
Table 2.24 Serono’s Hormonal Infertility Product Portfolio, 2005
Table 2.25 Estimated Global Sales (US$) and Annual Growth (%) of Serono’s Hormonal Infertility Products, 2005-2012
Table 2.26 Drugs in Research and Development for Infertility, 2005
Table 3.1 Female Oral Contraceptives in Development, 2005
Table 3.2 Nonoral Female Contraceptives in Development, 2005
Table 3.3 Male Contraceptives in Development, 2005
Table 3.4 Drugs in Development for Infertility, 2005
Table 4.1 Global Drug Market for Hormonal Contraception and Infertility (US$m), 2004-2012
Table 4.2 Therapy Area Forecasts for Hormonal Contraceptives and Infertility Drugs, 2012 & 2020

List of Figures
Figure 1.1 Lifestyle Disorder Characteristics Associated with Contraception
Figure 1.2 Lifestyle Factors Affecting Fertility
Figure 2.1 Estimated Sales (US$) and Forecasts of Hormonal Contraceptives and Infertility Drug Sectors, 2004-2012
Figure 2.2 Estimated Global Market Share for Hormonal Contraceptives and Infertility Drug Sectors, 2005 & 2012
Figure 4.1 Hormonal Contraceptive and Infertility Therapy Area Forecasts, 2005 & 2012 (US$m)
Figure 4.2 Market Share of Hormonal Contraception and Infertility Therapy Areas, 2005 & 2012
Figure 4.3 Comparative Analysis of Leading Contraceptives and Infertility Drug Products, 2004-2012 (US$m)
Figure 4.4 Key Contraception Prospects in the Development Pipeline, 2005
Figure 4.5 Key Infertility Drug Prospects in the Development Pipeline, 2005